AMYLIN PHARMACEUTICALS INC 4
4 · AMYLIN PHARMACEUTICALS INC · Filed Aug 10, 2012
Insider Transaction Report
Form 4
ADAMS ADRIAN
Director
Transactions
- Expiration (Short)
Non-Qualified Stock Option (right to buy)
2012-08-08−20,000→ 0 totalExercise: $46.58Exp: 2014-10-29→ Common Stock (20,000 underlying) - Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−20,000$620,000→ 0 totalExercise: $13.18Exp: 2018-05-24→ Common Stock (20,000 underlying) - Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−20,000$620,000→ 0 totalExercise: $21.52Exp: 2017-04-29→ Common Stock (20,000 underlying) - Expiration (Short)
Non-Qualified Stock Option (right to buy)
2012-08-08−12,000→ 0 totalExercise: $31.77Exp: 2015-05-30→ Common Stock (12,000 underlying) - Other
Common Stock
2012-08-08$31.00/sh−10,800$334,800→ 10,200 total - Other
Common Stock
2012-08-08$31.00/sh−10,200$316,200→ 0 total - Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−20,000$620,000→ 0 totalExercise: $11.68Exp: 2016-05-27→ Common Stock (20,000 underlying) - Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−20,000$620,000→ 0 totalExercise: $27.30Exp: 2019-05-15→ Common Stock (20,000 underlying)
Footnotes (4)
- [F1]Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc. Includes 3,000 unvested restricted stock units that were cancelled at the effective time of the merger pursuant to the merger agreement in exchange for the right to receive cash payment for such restricted stock units at a price of $31.00 per restricted stock unit.
- [F2]Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc.
- [F3]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., these options, whether or not vested, were fully vested immediately prior to and cancelled at the effective time of the merger in exchange for the right to receive cash payment in the amount of $31.00 per option less the exercise price of such option.
- [F4]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., all options held by the reporting person with an exercise price above $31.00 per share were cancelled upon consummation of the merger.